ine2b4zs

Property	Value
?:abstract	The aim of this study was to evaluate the impact of early treatment with corticosteroids on SARS-CoV-2 clearance in hospitalized COVID-19 patients Retrospective analysis on patients admitted to the San Raffaele Hospital (Milan, Italy) with moderate/severe COVID-19 and availability of at least two nasopharyngeal swabs The primary outcome was the time to nasopharyngeal swab negativization A multivariable Cox model was fitted to determine factors associated with nasopharyngeal swab negativization Of 280 patients included, 59 (21 1%) patients were treated with steroids Differences observed between steroid users and non-users included the proportion of patients with a baseline PaO2/FiO(2)70 years, a shorter duration of symptoms at admission, a baseline PaO2/FiO(2)>200 mmHg, and a lymphocyte count at admission>1 0x10(9)/L SARS-CoV-2 clearance was not associated with corticosteroid use Our study shows that delayed SARS-CoV-2 clearance in moderate/severe COVID-19 is associated with older age and a more severe disease, but not with an early use of corticosteroids The aim of this study was to evaluate the impact of early treatment with corticosteroids on SARS-CoV-2 clearance in hospitalized COVID-19 patients. Retrospective analysis on patients admitted to the San Raffaele Hospital (Milan, Italy) with moderate/severe COVID-19 and availability of at least two nasopharyngeal swabs. The primary outcome was the time to nasopharyngeal swab negativization. A multivariable Cox model was fitted to determine factors associated with nasopharyngeal swab negativization. Of 280 patients included, 59 (21.1%) patients were treated with steroids. Differences observed between steroid users and non-users included the proportion of patients with a baseline PaO2/FiO2 ≤ 200 mmHg (45.8% vs 34.4% in steroids and non-steroids users, respectively; p = 0.023) or ≤ 100 mmHg (16.9% vs 12.7%; p = 0.027), and length of hospitalization (20 vs 14 days; p < 0.001). Time to negativization of nasopharyngeal swabs was similar in steroid and non-steroid users (p = 0.985). According to multivariate analysis, SARS-CoV-2 clearance was associated with age ≤ 70 years, a shorter duration of symptoms at admission, a baseline PaO2/FiO2 > 200 mmHg, and a lymphocyte count at admission > 1.0 × 109/L. SARS-CoV-2 clearance was not associated with corticosteroid use. Our study shows that delayed SARS-CoV-2 clearance in moderate/severe COVID-19 is associated with older age and a more severe disease, but not with an early use of corticosteroids.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/ine2b4zs_hasAnnotation_C1457887> <https://research.tib.eu/covid-19/entity/ine2b4zs_hasAnnotation_C1825598> <https://research.tib.eu/covid-19/entity/ine2b4zs_hasAnnotation_C1826357> <https://research.tib.eu/covid-19/entity/ine2b4zs_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Spagnuolo%2C_V%3B_Guffanti%2C_M%3B_Galli%2C_L%3B_Poli%2C_A%3B_Querini%2C_P_Rovere%3B_Ripa%2C_M%3B_Clementi%2C_M%3B_Scarpellini%2C_P%3B_Lazzarin%2C_A%3B_Tresoldi%2C_M%3B_Dagna%2C_L%3B_Zangrillo%2C_A%3B_Ciceri%2C_F%3B_Castagna%2C_A> <https://research.tib.eu/covid-19/entity/Spagnuolo%2C_V.%3B_Guffanti%2C_M.%3B_Galli%2C_L.%3B_Poli%2C_A.%3B_Querini%2C_P._R.%3B_Ripa%2C_M.%3B_Clementi%2C_M.%3B_Scarpellini%2C_P.%3B_Lazzarin%2C_A.%3B_Tresoldi%2C_M.%3B_Dagna%2C_L.%3B_Zangrillo%2C_A.%3B_Ciceri%2C_F.%3B_Castagna%2C_A.%3B_Grp%2C_C._OVID-BioB_Study>
?:journal	Sci_Rep Scientific_Reports
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/ine2b4zs_HAS_C5203676_COEXISTS_WITH_C5203670>
?:source	WHO
?:title	Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#1060322 #960333
?:year	2020

Property

Value

?:abstract

The aim of this study was to evaluate the impact of early treatment with corticosteroids on SARS-CoV-2 clearance in hospitalized COVID-19 patients Retrospective analysis on patients admitted to the San Raffaele Hospital (Milan, Italy) with moderate/severe COVID-19 and availability of at least two nasopharyngeal swabs The primary outcome was the time to nasopharyngeal swab negativization A multivariable Cox model was fitted to determine factors associated with nasopharyngeal swab negativization Of 280 patients included, 59 (21 1%) patients were treated with steroids Differences observed between steroid users and non-users included the proportion of patients with a baseline PaO2/FiO(2)70 years, a shorter duration of symptoms at admission, a baseline PaO2/FiO(2)>200 mmHg, and a lymphocyte count at admission>1 0x10(9)/L SARS-CoV-2 clearance was not associated with corticosteroid use Our study shows that delayed SARS-CoV-2 clearance in moderate/severe COVID-19 is associated with older age and a more severe disease, but not with an early use of corticosteroids
The aim of this study was to evaluate the impact of early treatment with corticosteroids on SARS-CoV-2 clearance in hospitalized COVID-19 patients. Retrospective analysis on patients admitted to the San Raffaele Hospital (Milan, Italy) with moderate/severe COVID-19 and availability of at least two nasopharyngeal swabs. The primary outcome was the time to nasopharyngeal swab negativization. A multivariable Cox model was fitted to determine factors associated with nasopharyngeal swab negativization. Of 280 patients included, 59 (21.1%) patients were treated with steroids. Differences observed between steroid users and non-users included the proportion of patients with a baseline PaO2/FiO2 ≤ 200 mmHg (45.8% vs 34.4% in steroids and non-steroids users, respectively; p = 0.023) or ≤ 100 mmHg (16.9% vs 12.7%; p = 0.027), and length of hospitalization (20 vs 14 days; p < 0.001). Time to negativization of nasopharyngeal swabs was similar in steroid and non-steroid users (p = 0.985). According to multivariate analysis, SARS-CoV-2 clearance was associated with age ≤ 70 years, a shorter duration of symptoms at admission, a baseline PaO2/FiO2 > 200 mmHg, and a lymphocyte count at admission > 1.0 × 109/L. SARS-CoV-2 clearance was not associated with corticosteroid use. Our study shows that delayed SARS-CoV-2 clearance in moderate/severe COVID-19 is associated with older age and a more severe disease, but not with an early use of corticosteroids.

is ?:annotates of